NICE introduces cost sharing scheme for sight drugBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a1487 (Published 29 August 2008) Cite this as: BMJ 2008;337:a1487
- Roger Dobson
Patients in England and Wales with one of the most common causes of blindness will be able to be treated with injections of ranibizumab (Lucentis) on the NHS under a cost sharing scheme announced by the National Institute for Health and Clinical Excellence (NICE).
The final guidance states that the NHS should pay for the first 14 injections of ranibizumab for patients with the wet form of age related macular degeneration (AMD), with the manufacturer picking up the bill for any more that are needed. The drug costs more than £10 000 (€12 400, $18 280) for each eye treated with 14 injections.
A second drug for the condition, pegaptanib (Macugen), has not been …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial